Defective Trustee Substitution Goes to Capacity—Not Article III Standing—and May Be Cured by Waiver/Ratification

1. Introduction

In UMB Bank, N.A. v. Bristol-Myers Squibb Company (2d Cir. Aug. 13, 2026), the Second Circuit vacated the dismissal of a high-stakes contract action brought under a Contingent Value Rights Agreement (“CVR Agreement”) created in connection with Bristol-Myers Squibb’s acquisition of Celgene.

The plaintiff, UMB Bank, N.A., sued “solely in its capacity as Trustee” under the CVR Agreement, alleging Bristol-Myers breached its obligation to use “Diligent Efforts” to obtain FDA approvals that would have triggered a one-time $9 per CVR payout (an aggregate exposure exceeding $6 billion). The defendant, Bristol-Myers Squibb Company, ultimately contended that UMB was never properly substituted as trustee because the substitution instrument was executed by beneficial owners rather than the “Holders” registered in the security register (principally DTC’s nominee, Cede & Co.).

The central issues on appeal were: (i) whether alleged defects in UMB’s appointment implicated Article III standing (and thus subject-matter jurisdiction) or instead merely capacity to sue; (ii) whether Bristol-Myers (and Equiniti, the original trustee) waived or ratified UMB’s appointment by accepting and publicly noticing the substitution; and (iii) whether the Second Circuit could entertain Bristol-Myers’ conditional cross-appeal from an interlocutory order denying an earlier motion to dismiss.

2. Summary of the Opinion

The Second Circuit held:

  • Standing vs. capacity: Even if UMB’s trustee substitution failed to comply with the CVR Agreement’s formal requirements, that defect concerns capacity to sue, not Article III standing. The alleged injury was to the trust and its beneficiaries (CVR holders), which is cognizable and redressable in federal court.
  • Waiver/ratification: On this record, Equiniti’s and Bristol-Myers’ acceptance of UMB as trustee—after being informed the signatories were not registered holders—combined with evidence that a majority of beneficial owners approved the substitution, precluded Bristol-Myers from challenging UMB’s capacity. Whether labeled “waiver” or “ratification,” the effect was the same.
  • Cross-appeal dismissed: The court dismissed Bristol-Myers’ conditional cross-appeal for lack of appellate jurisdiction because the denial of a motion to dismiss is interlocutory and the issues were not “inextricably intertwined” with the appealable jurisdictional ruling.

Disposition: the court VACATED the dismissal, DISMISSED the cross-appeal, and REMANDED.

3. Analysis

3.1. Precedents Cited

Article III standing framework

  • Spokeo, Inc. v. Robins: Cited for the purpose of standing doctrine—to keep federal courts within traditionally understood judicial power—and for the concept of “legal wrong” requiring an appropriate litigant. The Second Circuit used Spokeo to frame the inquiry, then emphasized that the relevant injury here was to the trust/beneficiaries, not to UMB personally.
  • Lujan v. Defenders of Wildlife: Provided the familiar three-part test—injury in fact, causation, and redressability. The court treated those elements as satisfied because the CVR trust/beneficiaries allegedly lost billions due to breach and a favorable judgment would redress that loss.

Trustees and representative litigation

  • Sprint Communications Co., L.P. v. APCC Services, Inc.: Anchored the proposition that trustees (and analogous representatives) may sue to benefit others; they need not be personally injured so long as the represented entity/beneficiaries have a cognizable stake. This supported the court’s rejection of Bristol-Myers’ “no personal injury to UMB” argument.
  • Thole v. U.S. Bank N.A.: Invoked by Bristol-Myers to argue that a plaintiff without a personal stake cannot proceed as a “representative.” The Second Circuit distinguished Thole: the Thole plaintiffs were not duly acting trustees and, critically, defined-benefit plan participants are not situated like private trust beneficiaries whose payout depends on trust performance. Here, the suit was brought by a putative trustee under a trust indenture designed to protect CVR holders’ economic interests.

Capacity vs. standing; “real party in interest” and pleading defects

  • SM Kids, LLC v. Google LLC: Cited for the crucial distinction between Article III standing and so-called “contractual standing” (a merits/capacity-type inquiry about the right to enforce a contract). The court deployed SM Kids to reclassify the dispute from jurisdictional to non-jurisdictional.
  • Allan Applestein TTEE FBO D.C.A. v. Province of Buenos Aires: Highly influential analog. There, a beneficial owner’s failure to obtain DTC authorization was treated as a non-jurisdictional defect—effectively a capacity/authority issue subject to waiver and capable of cure—rather than a standing defect. The Second Circuit relied on Applestein’s logic to treat DTC/registered-holder formalities here as capacity-related.
  • Fund Liquidation Holdings LLC v. Bank of America Corp.: Used to reject “nullity” thinking (that filing by an improper plaintiff destroys jurisdiction irreparably). Even where the originally named plaintiff lacks standing, the case need not be a jurisdictional nullity if a proper party with standing exists to prosecute the claim. The opinion’s reasoning supported viewing “wrong representative” problems as fixable without collapsing Article III jurisdiction.
  • Revitalizing Auto Communities Environmental Response (RACER) Trust v. National Grid USA: Reinforced that capacity to sue is non-jurisdictional, can be waived, and is governed by Rule 17 principles and state law on who may sue for the trust.
  • Brown v. Keller and Firestone v. Galbreath: Sixth Circuit authorities treating disputes about whether plaintiffs were proper trustees/representatives as capacity questions rather than jurisdictional standing. Brown was particularly “squarely on point” in the Second Circuit’s framing.

Standards of review and jurisdictional timing

  • Vermont Right to Life Committee, Inc. v. Sorrell: Cited for de novo review of legal conclusions after a standing dismissal.
  • Hussein v. Maait: Cited for clear-error review of factual findings where the district court relied on evidence beyond the complaint in assessing jurisdiction.
  • Shann v. Dunk: Referenced for clear-error review of contract-related factfinding (used here to frame review of ratification/waiver-related findings).

New York waiver/estoppel/ratification doctrine

  • Fundamental Portfolio Advisors, Inc. v. Tocqueville Asset Management, L.P.: Provided the definition of waiver—knowing, voluntary, intentional abandonment—and explained that waiver can be shown by affirmative conduct or inaction that clearly manifests relinquishment.
  • Nassau Trust Co. v. Montrose Concrete Products Corp.: Cited for the practical overlap among waiver, estoppel, bad faith, and unconscionable conduct, supporting the court’s willingness to treat labels as secondary to substance.
  • In re Adelphia Recovery Trust and Schenck v. State Line Telephone Co.: Supplied the definition of ratification and the principle that ratification can be express, implied, or accomplished by silence/inaction with knowledge of rights.

Appellate jurisdiction over conditional cross-appeals

  • Hill v. City of New York: Denial of a motion to dismiss is ordinarily non-final and not immediately appealable.
  • Bolmer v. Oliveira and Lamar Advertising of Penn, LLC v. Town of Orchard Park, New York: Defined the narrow scope of pendent appellate jurisdiction—only when issues are “inextricably intertwined” or necessary for meaningful review. The court used these to dismiss the cross-appeal.

3.2. Legal Reasoning

(a) Why the defect was not Article III standing

The court’s core move was to identify the proper locus of injury. The complaint alleged that Bristol-Myers’ breach deprived the CVR trust/beneficiaries of the contingent payout. Because the suit was brought “solely in [UMB’s] capacity as Trustee,” the presence or absence of UMB’s personal injury was irrelevant. The trust’s alleged loss supplied injury-in-fact; Bristol-Myers’ alleged contractual noncompliance supplied causation; damages or equitable relief would redress the injury.

From there, the court treated Bristol-Myers’ “you weren’t properly appointed” argument as one about who is authorized to sue, not whether a case or controversy exists. That is the hallmark of a capacity/real-party-in-interest dispute addressed by Rule 17 concepts, waiver principles, and practical curability—rather than a jurisdictional defect that can be raised at any time and cannot be cured.

(b) Why waiver/ratification barred Bristol-Myers’ challenge

Assuming arguendo that the CVR Agreement required action by registered “Holders” (i.e., DTC/Cede & Co.) rather than beneficial owners, the court held UMB could proceed because Bristol-Myers and Equiniti accepted UMB as trustee with knowledge of the key facts:

  • Equiniti told Bristol-Myers: “None of the shareholders listed are registered holders.”
  • Bristol-Myers cited the “Majority Holders” requirement and the Agreement definition.
  • Bristol-Myers nonetheless pushed for proof of ownership that was, in substance, proof of beneficial ownership.
  • After receiving that proof, Bristol-Myers and Equiniti issued a public “Notice to Holders” announcing UMB’s substitution.

Given those facts, the court found clearly erroneous the district court’s view that acceptance “credibly appears” to have been mere confusion rather than knowing relinquishment/affirmance. Under New York law, that sequence constituted a clear manifestation of waiver and/or a knowing ratification of an otherwise unauthorized act. Importantly, enforcing waiver/ratification here did not undermine beneficiary protections because a majority of beneficial owners supported the substitution; the flaw was at most in formalities, not in substantive investor consent.

(c) Why the cross-appeal was dismissed

Once the Second Circuit decided the case should be remanded (because dismissal for lack of subject-matter jurisdiction was wrong and capacity could not be defeated on this record), Bristol-Myers’ request to review the earlier denial of its first motion to dismiss ran into final-judgment rules. The denial order was interlocutory, and the court refused pendent appellate jurisdiction because the notice-of-default issue required different contractual provisions and was not necessary to review the standing/capacity ruling.

3.3. Impact

  • Reclassification of “improper representative” disputes: The decision strengthens a Second Circuit line treating disputes over whether the plaintiff is the correct trustee/authorized actor as capacity questions, reducing the availability of late-breaking “jurisdictional” ambushes.
  • Greater role for waiver/ratification in trustee/indenture litigation: Parties who publicly accept a substitution (or otherwise act consistently with it) risk being held to that acceptance, particularly where investor/beneficiary interests are not prejudiced.
  • DTC/registered-holder mechanics: The opinion signals judicial skepticism toward using the registered-holder/beneficial-owner divide to defeat litigation after the parties have treated beneficial-owner approvals as sufficient in practice.
  • Appellate strategy constraint: Conditional cross-appeals from non-final orders remain difficult; litigants cannot assume pendent appellate jurisdiction will attach merely because a jurisdictional issue is on appeal.

4. Complex Concepts Simplified

  • Article III standing: A constitutional requirement that there be a real dispute (injury, causation, redressability). If missing, federal courts lack power to decide the case.
  • Capacity to sue: A non-jurisdictional question about whether this particular plaintiff is the proper legal actor to bring the claim (e.g., the correct trustee). Capacity defects can often be waived, cured, or ratified.
  • Registered holder vs. beneficial owner (DTC structure): Securities are often registered in the name of DTC’s nominee (e.g., Cede & Co.) even though investors are the true economic owners. Contracts may assign formal voting/consent rights to the registered holder, creating technical pitfalls if beneficial owners act directly.
  • Waiver vs. ratification: Waiver is giving up a contractual protection; ratification is affirming an act that might otherwise be unauthorized. Both can occur through conduct, including public statements and consistent performance.
  • Pendent appellate jurisdiction: A narrow doctrine allowing review of some non-appealable issues only if they are inseparable from the appealable issue or necessary to decide it.

5. Conclusion

UMB Bank, N.A. v. Bristol-Myers Squibb Company establishes (and consolidates within Second Circuit doctrine) a practical and consequential rule: alleged defects in a trustee’s appointment typically affect capacity, not Article III standing, where the underlying trust/beneficiaries suffered a cognizable injury and the suit is brought in a representative trustee capacity. The court further underscores that sophisticated parties who knowingly accept a trustee substitution—especially by issuing public notices and treating the substitute as trustee—may be held to that acceptance under New York waiver and ratification principles. Finally, the decision reaffirms strict limits on interlocutory appellate review, dismissing a conditional cross-appeal that was not inextricably intertwined with the appealable issues.